1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Inspira Enters Agreement with Glo-Med to Distribute Its FDA Cleared INSPIRA ART100 in US

26 Oct 2024
Admin
News Article

Inspira Enters Agreement with Glo-Med to Distribute Its FDA Cleared INSPIRA ART100 in US

Inspira enters agreement with Glo-Med to distribute its US FDA cleared CPB procedures, INSPIRA ART100 in US

Overview

Inspira Technologies OXY B.H.N. Ltd., a groundbreaking life support technology company, announced that it has entered into an agreement with Glo-Med Networks Inc (Glo-Med), which will serve as Inspira's primary distributor in the United States. Glo-Med's distribution facility will serve as a support center for the deployment of the INSPIRA ART100 in the United States. The INSPIRA ART100 is US Food and Drug Administration (FDA) 510(k)-cleared for Cardiopulmonary Bypass (CPB) procedures.

Inspira Mission for Acute Respiratory Failure Patients

Inspira aims to revolutionize life support for millions of acute respiratory failure patients each year with the company's proprietary INSPIRA ART device being designed to monitor and elevate declining blood saturation levels in minutes without a mechanical ventilator.
Targeting 20 million patients each year, the INSPIRA ART has a potential estimated $19 billion market opportunity.
This agreement and distribution facility aims to enhance the company's operational efficiency and customer service capabilities in the US market.
Toward the planned deployment of the INSPIRA ART100 in 2024 and looking ahead, the company's goal is to introduce physicians and perfusionists to Inspira's technologies and brand proposition in preparation for the future planned deployment of the flagship INSPIRA ART.

Role of Distribution Facility

The distribution facility, located in Florida, will play an important role in supporting the deployment and maintenance of the INSPIRA ART100 system and will potentially facilitate the commercialization of additional products in the US market in the future.
The medical distribution and service facility will be fully operated by Glo-Med and will serve as a central hub for Inspira's logistics operations, pursuant to the distribution agreement, ensuring the timely and efficient distribution of the company's innovative medical devices.
The facility will house a dedicated customer support team providing comprehensive support services to healthcare providers using Inspira's products.
Additionally, the facility will provide original equipment manufacturer certified after-market services through a partnership with Med-Stat Consulting Services (Med-Stat), a reputable national biomedical engineering services firm.
Med-Stat was founded in 2003 and provides onsite and depot medical equipment servicing for the largest and most reputable healthcare facilities in the US.

Words from the President: Inspira Technologies

Joe Hayon, co-founder and president of Inspira Technologies, stated, "This distribution agreement represents a crucial milestone in our efforts to introduce Inspira's innovative technologies to the market. With Glo-Med managing the deployment and maintenance of the INSPIRA ART 100 system in the US, I believe that we are well-positioned for the future launch of our flagship INSPIRA ART and other products in our pipeline."

Words from the CEO: Glo-Med

Matus Knoblich, CEO of Glo-Med, stated, ""I believe that the coupling of Glo-Med's distribution network and capabilities with the industry leading service provided by Med-Stat will create a fully vertically integrated business model where customers can receive the highest level of service and support within the industry sector. Both companies will be working with the same mission in mind: growth and expansion of the Inspira Technologies brand coupled with a fully supported user experience. We believe that this will lead to success for all participants.""

About the Company: Inspira Technologies

Inspira Technologies is an innovative medical technology company in the life support and respiratory treatment arena.
The company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), a groundbreaking device poised to revolutionize the $19 billion mechanical ventilation market.